Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia

Novel agents, including Bruton tyrosine kinase inhibitors (BTKis), have become the standard of care for patients with chronic lymphocytic leukemia (CLL). We conducted a real-world retrospective analysis of patients with CLL treated with acalabrutinib vs ibrutinib using the Flatiron Health database....

Descripción completa

Detalles Bibliográficos
Autores principales: Roeker, Lindsey E., DerSarkissian, Maral, Ryan, Kellie, Chen, Yan, Duh, Mei Sheng, Wahlstrom, Svea K., Hakre, Shweta, Yu, Louise, Guo, Helen, Mato, Anthony R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Health Services and Outcomes
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10424141/
https://www.ncbi.nlm.nih.gov/pubmed/37163361
http://dx.doi.org/10.1182/bloodadvances.2023009739

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10424141/
https://www.ncbi.nlm.nih.gov/pubmed/37163361
http://dx.doi.org/10.1182/bloodadvances.2023009739

Ejemplares similares